Project Details
Description
A Multicenter Retrospective Study to understand the clinical characteristics, treatment pathway and resource utilization for patients with chronic lymphocytic leukemia A retrospective, multi-centre, observational study to describe disease characteristics, treatment patterns, treatment-related outcomes, and resource utilization for Chronic Lymphocytic Leukemia (CLL) patients in multiple international regions
Layman's description
CREEK is a retrospective, observational, registry-based study including patients with an incidental diagnosis of CLL and started treatment (1st line, 2nd line, or Subsequent lines of treatment) within the period between 01 June 2016 and 12 months before data collection as identified from the patient records (from participating hospitals across the GCC States and the International region countries) with at least 12 months of follow-up, after starting on treatment.
Moreover, the study will include a pilot cohort in the GCC as an exploratory objective to describe the clinical and patient characteristics for the treatment-naive CLL patient
Moreover, the study will include a pilot cohort in the GCC as an exploratory objective to describe the clinical and patient characteristics for the treatment-naive CLL patient
| Acronym | CREEK |
|---|---|
| Status | Finished |
| Effective start/end date | 3/12/21 → 31/08/23 |
Collaborative partners
- AstraZeneca (lead)
- Abu Dhabi Health Services Company
Keywords
- Chronic lymphocytic leukemia
- CLL
- Neoplasms by Histologic Type
- Neoplasms
- Hematologic Diseases
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Immune System Diseases
- Leukemia, B-Cell
- Chronic Disease
- Disease Attributes
- Pathologic Processes
- Leukemia
- Leukemia, Lymphoid
- Leukemia, Lymphocytic, Chronic, B-Cell
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.